ライフサイエンスコーパス: Kaposi

1 Kaposi sarcoma (KS) herpesvirus-associated multicentric

2 Kaposi sarcoma (KS) incidence has decreased since combin

3 Kaposi sarcoma (KS) is a complication of KS-associated h

4 Kaposi sarcoma (KS) remains a frequent cancer in human i

5 Kaposi sarcoma (KS) risk is affected by perturbed immuni

6 Kaposi sarcoma (KS), a human herpes virus 8 (HHV-8; also

7 Kaposi sarcoma herpesvirus (KSHV) is the cause of Kaposi

8 Kaposi sarcoma herpesvirus (KSHV) is the most common cau

9 Kaposi sarcoma herpesvirus (KSHV) persists as a latent n

10 Kaposi sarcoma herpesvirus (KSHV)-associated multicentri

11 Kaposi sarcoma herpesvirus (KSHV)-associated multicentri

12 Kaposi sarcoma is caused by infection of Kaposi sarcoma-

13 Kaposi sarcoma is the most common human herpesvirus 8 (H

14 Kaposi sarcoma was observed in 9 cases.

15 Kaposi sarcoma-associated herpesvirus (KSHV) has a causa

16 Kaposi sarcoma-associated herpesvirus (KSHV) is an oncog

17 Kaposi sarcoma-associated herpesvirus (KSHV), also known

18 Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL

19 Kaposi's sarcoma (KS) as the most common AIDS-associated

20 Kaposi's sarcoma (KS) is a disease of multifocal vascula

21 Kaposi's sarcoma (KS) is an AIDS-defining cancer with ab

22 Kaposi's sarcoma (KS) is common in Africa, but economic

23 Kaposi's sarcoma (KS)-associated herpesvirus (KSHV) infe

24 Kaposi's sarcoma (KS)-associated herpesvirus (KSHV) is a

25 Kaposi's sarcoma associated herpesvirus (KSHV) establish

26 Kaposi's sarcoma is a highly vascular tumor, and recentl

27 Kaposi's sarcoma is a highly vascularized, endothelial c

28 Kaposi's sarcoma is one of the most common malignancies

29 Kaposi's sarcoma-associated herpes virus (KSHV) is the c

30 Kaposi's sarcoma-associated herpes virus (KSHV) polyaden

31 Kaposi's sarcoma-associated herpesvirus (KSHV) and Epste

32 Kaposi's sarcoma-associated herpesvirus (KSHV) and the c

33 Kaposi's sarcoma-associated herpesvirus (KSHV) causes Ka

34 Kaposi's sarcoma-associated herpesvirus (KSHV) causes tw

35 Kaposi's sarcoma-associated herpesvirus (KSHV) encodes 1

36 Kaposi's sarcoma-associated herpesvirus (KSHV) encodes 1

37 Kaposi's sarcoma-associated herpesvirus (KSHV) encodes m

38 Kaposi's sarcoma-associated herpesvirus (KSHV) encodes n

39 Kaposi's sarcoma-associated herpesvirus (KSHV) encodes t

40 Kaposi's sarcoma-associated herpesvirus (KSHV) enters hu

41 Kaposi's sarcoma-associated herpesvirus (KSHV) establish

42 Kaposi's sarcoma-associated herpesvirus (KSHV) evades ho

43 Kaposi's sarcoma-associated herpesvirus (KSHV) has a cau

44 Kaposi's sarcoma-associated herpesvirus (KSHV) has a sig

45 Kaposi's sarcoma-associated herpesvirus (KSHV) has been

46 Kaposi's sarcoma-associated herpesvirus (KSHV) has tropi

47 Kaposi's sarcoma-associated herpesvirus (KSHV) infection

48 Kaposi's sarcoma-associated herpesvirus (KSHV) infection

49 Kaposi's sarcoma-associated herpesvirus (KSHV) infects m

50 Kaposi's sarcoma-associated herpesvirus (KSHV) interacts

51 Kaposi's sarcoma-associated herpesvirus (KSHV) is a DNA

52 Kaposi's sarcoma-associated herpesvirus (KSHV) is a gamm

53 Kaposi's sarcoma-associated herpesvirus (KSHV) is a gamm

54 Kaposi's sarcoma-associated herpesvirus (KSHV) is a huma

55 Kaposi's sarcoma-associated herpesvirus (KSHV) is a huma

56 Kaposi's sarcoma-associated herpesvirus (KSHV) is a huma

57 Kaposi's sarcoma-associated herpesvirus (KSHV) is a huma

58 Kaposi's sarcoma-associated herpesvirus (KSHV) is a huma

59 Kaposi's sarcoma-associated herpesvirus (KSHV) is a prom

60 Kaposi's sarcoma-associated herpesvirus (KSHV) is an onc

61 Kaposi's sarcoma-associated herpesvirus (KSHV) is associ

62 Kaposi's sarcoma-associated herpesvirus (KSHV) is causat

63 Kaposi's sarcoma-associated herpesvirus (KSHV) is etiolo

64 Kaposi's sarcoma-associated herpesvirus (KSHV) is etiolo

65 Kaposi's sarcoma-associated herpesvirus (KSHV) is etiolo

66 Kaposi's sarcoma-associated herpesvirus (KSHV) is linked

67 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

68 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

69 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

70 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

71 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

72 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

73 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

74 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

75 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

76 Kaposi's sarcoma-associated herpesvirus (KSHV) is the et

77 Kaposi's sarcoma-associated herpesvirus (KSHV) is the et

78 Kaposi's sarcoma-associated herpesvirus (KSHV) is the et

79 Kaposi's sarcoma-associated herpesvirus (KSHV) is the et

80 Kaposi's sarcoma-associated herpesvirus (KSHV) is the et

81 Kaposi's sarcoma-associated herpesvirus (KSHV) latency a

82 Kaposi's sarcoma-associated herpesvirus (KSHV) maintains

83 Kaposi's sarcoma-associated herpesvirus (KSHV) ORF57 pla

84 Kaposi's sarcoma-associated herpesvirus (KSHV) ORF6 is h

85 Kaposi's sarcoma-associated herpesvirus (KSHV), a DNA tu

86 Kaposi's sarcoma-associated herpesvirus (KSHV), also kno

87 Kaposi's sarcoma-associated herpesvirus (KSHV), the caus

88 Kaposi's sarcoma-associated herpesvirus (KSHV), the etio

89 Kaposi's sarcoma-associated herpesvirus (KSHV), the etio

90 Kaposi's sarcoma-associated herpesvirus (KSHV)-related m

91 Kaposi's sarcoma-associated herpesvirus (KSHV, also call

92 Kaposi's sarcoma-associated herpesvirus is a leading cau

93 Kaposi's sarcoma-associated herpesvirus is the causative

94 Kaposi's sarcoma-associated herpesvirus-encoded vFLIP K1

95 Kaposi's sarcoma-associated herpesvirus-encoded viral FL

96 e infected with human herpesvirus 8 (HHV-8) (Kaposi's sarcoma [KS]-associated herpesvirus) and have a

97 osely related to human herpesvirus 8 (HHV-8)/Kaposi's Sarcoma-associated herpesvirus (KSHV), and it i

98 V1) lineage consists of human herpesvirus 8, Kaposi's sarcoma-associated herpesvirus (KSHV), and clos

99 egy of selectively isolating VLVs by using a Kaposi's sarcoma-associated herpesvirus (KSHV) mutant th

100 al interferon regulatory factor 1 (vIRF1), a Kaposi sarcoma herpesvirus protein, destabilizes p53 by

101 The responsible agent, Kaposi's sarcoma-associated herpesvirus (KSHV; HHV8), ex

102 Although Kaposi's sarcoma-associated herpesvirus (KSHV) ORF52 (al

103 Co-infection with HIV-1 and Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

104 -OIs were Pneumocystis pneumonia (39.1%) and Kaposi sarcoma (20.1%).

105 an T cell lymphotropic virus-1 (HTLV-1), and Kaposi's sarcoma herpesvirus (KSHV).

106 lated diagnoses, oesophageal candidiasis and Kaposi's sarcoma, rose from almost zero to very high lev

107 genomes, those of human cytomegalovirus and Kaposi's sarcoma-associated herpesvirus, revealing trans

108 homas, multicentric Castleman's disease, and Kaposi's sarcoma.

109 The oncogenic gamma-herpesviruses EBV and Kaposi sarcoma-associated herpesvirus are ubiquitous hum

110 n tumor viruses Epstein-Barr virus (EBV) and Kaposi sarcoma-associated herpesvirus (KSHV) establish p

111 Epstein-Barr virus (EBV) and Kaposi's sarcoma herpesvirus (KSHV), formally designated

112 lytic cycles of Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) are induc

113 maherpesviruses Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) cause lif

114 aherpesviruses, Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV), is assoc

115 50 promoters of Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV), respecti

116 maherpesviruses Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV), which ar

117 G, and panel), Epstein-Barr Virus (EBV), and Kaposi's Sarcoma-associated Herpes Virus (KSHV) in a fin

118 ovirus (HCMV), Epstein-Barr virus (EBV), and Kaposi's sarcoma-associated herpesvirus, establish laten

119 rcoma, epithelioid hemangioendothelioma, and Kaposi sarcoma are classified according to the line of d

120 elated malignancies, including lymphomas and Kaposi's sarcoma.

121 ed to murine gammaherpesvirus 68 (MHV68) and Kaposi's sarcoma-associated herpesvirus (KSHV) that esta

122 tors (e.g., herpes simplex virus nectin1 and Kaposi's sarcoma-associated herpesvirus EphA2), or assoc

123 ncluding primary effusion lymphoma (PEL) and Kaposi's sarcoma (KS).

124 mutant with prototype foamy virus (PFV) and Kaposi's sarcoma herpesvirus (KSHV) tethering sequences

125 view the evidence for Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus as causal lympho

126 c mechanisms by which Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus cause B-cell lym

127 ciated polyomavirus, Epstein-Barr virus, and Kaposi's sarcoma-associated herpesvirus, because GEMs ha

128 y focal assembly of RNA polymerase II around Kaposi's sarcoma-associated herpesvirus (KSHV) genomes i

129 Human herpes virus 8 (HHV-8), also known as Kaposi's sarcoma associated herpesvirus (KSHV), is an on

130 gnancies except for specific tumors, such as Kaposi sarcoma and mantle cell lymphoma.

131 DNA tumor viruses such as Kaposi's sarcoma-associated herpesvirus (KSHV) are known

132 ovarian, breast, and lung cancer, as well as Kaposi's sarcoma.

133 nd angiogenic activities to HHV-8-associated Kaposi's sarcoma, primary effusion lymphoma (PEL), and m

134 ting it as a contributor to virus-associated Kaposi's sarcoma, primary effusion lymphoma (PEL), and m

135 recently showed that the interaction between Kaposi's sarcoma-associated herpesvirus (KSHV) tegument

136 emonstrate that RelA/NF-kappaB activation by Kaposi sarcoma herpesvirus (KSHV) latency protein vFLIP

137 erous proliferation of B cells, is caused by Kaposi's sarcoma-associated herpesvirus (KSHV).

138 nown inflammation related diseases caused by Kaposi's sarcoma-associated herpesvirus (KSHV).

139 rcoma (KS) is a multicentric tumor caused by Kaposi's sarcoma-associated herpesvirus.

140 vo infection of primary endothelial cells by Kaposi's sarcoma-associated herpesvirus (KSHV).

141 ically, the thymidine kinase (TK) encoded by Kaposi sarcoma-associated herpesvirus (KSHV) is an extre

142 ich tumor cells are consistently infected by Kaposi's sarcoma-associated herpesvirus and usually grow

143 B-cell lymphoma associated with infection by Kaposi's sarcoma-associated herpes virus (KSHV).

144 Nonmelanoma skin cancer, Kaposi sarcoma, and posttransplant lymphoproliferative d

145 9, 95% CI 1.67-1.72), AIDS-defining cancers (Kaposi's sarcoma [498.11, 477.82-519.03], non-Hodgkin ly

146 All PELs carry Kaposi sarcoma-associated herpesvirus (KSHV).

147 (KSHV), is an oncogenic virus that can cause Kaposi's sarcoma (KS).

148 sarcoma-associated herpesvirus (KSHV) causes Kaposi's sarcoma and primary effusion lymphoma.

149 ow that HHV-8, a DNA tumor virus that causes Kaposi's sarcoma, infects three types of dendritic cells

150 Human herpesvirus 8, which causes Kaposi sarcoma, expresses the MARCH family ubiquitin lig

151 Lytic activation of the cancer-causing Kaposi's sarcoma-associated herpesvirus (KSHV) is vital

152 Classic Kaposi sarcoma (cKS) is an inflammatory tumor caused by

153 We compared Kaposi sarcoma (KS) risk in adults who started antiretro

154 Conjunctival Kaposi's sarcoma developed in 1 patient.

155 we present an innovative approach to culture Kaposi's sarcoma-associated herpesvirus (KSHV) infected

156 metabolic complications, frequently develop Kaposi sarcoma.

157 posttransplant period, one of whom developed Kaposi sarcoma.

158 rus and the culprit behind the human disease Kaposi sarcoma (KS), an AIDS-defining malignancy.

159 neoplastic or lymphoproliferative diseases: Kaposi's sarcoma (KS), primary effusion lymphoma (PEL),

160 In lymphomas the Epstein-Barr virus (EBV), Kaposi's sarcoma herpesvirus (KSHV) and human T-lymphotr

161 fied infections by Epstein-Barr virus (EBV), Kaposi's sarcoma herpesvirus (KSHV), and human T-lymphot

162 revealed 3 distinct HHV-8-related entities: Kaposi sarcoma, HHV-8-associated multicentric Castleman

163 EL clinical samples, and three extracavitary Kaposi's sarcoma-associated herpesvirus-positive solid l

164 without HIV, respectively, were as follows: Kaposi sarcoma, 4.4% and 0.01%; non-Hodgkin lymphoma, 4.

165 decreased significantly across 1996-2012 for Kaposi's sarcoma, two subtypes of non-Hodgkin lymphoma,

166 erpesvirus (KSHV) is the causative agent for Kaposi sarcoma (KS), primary effusion lymphoma (PEL), an

167 pesvirus (KSHV) is the etiological agent for Kaposi's sarcoma (KS).

168 the organization of this protein complex for Kaposi's sarcoma-associated herpesvirus.

169 tive incidence and hazard rate decreased for Kaposi sarcoma and non-Hodgkin lymphoma.

170 Incidence was most elevated for Kaposi sarcoma (hazard ratio [HR], 9.1; 95% confidence i

171 e kinase A2 (EphA2) is an entry receptor for Kaposi's sarcoma-associated herpesvirus (KSHV) that is e

172 virus type 1 (HIV-1) infection and risk for Kaposi sarcoma, but behaviors associated with HHV-8 tran

173 gh cumulative incidences by age 75 years for Kaposi sarcoma, non-Hodgkin lymphoma, and lung cancer su

174 A-binding domains (DBDs), LANA homologs from Kaposi sarcoma-associated herpesvirus (KSHV) and MHV68 e

175 Using the dimeric protease (Pr) from Kaposi's sarcoma-associated herpesvirus (KSHV) as a mode

176 -like inhibitory protein (FLIP) protein from Kaposi sarcoma-associated herpesvirus activates the NF-k

177 omolog, the oncogenic human gammaherpesvirus Kaposi's sarcoma-associated herpesvirus/human herpesviru

178 The human gammaherpesvirus, Kaposi's sarcoma-associated herpesvirus (KSHV), is tight

179 Two closely related gammaherpesviruses, Kaposi's sarcoma-associated herpesvirus (KSHV) and rhesu

180 the replication of the oncogenic herpesvirus Kaposi's sarcoma-associated herpesvirus (KSHV), by targe

181 16) recognizes nuclear episomal herpesvirus (Kaposi's sarcoma-associated herpesvirus [KSHV], Epstein-

182 The human gamma herpesviruses, Kaposi sarcoma-associated virus (KSHV) and EBV, are asso

183 protein (SCP) of human tumor herpesviruses--Kaposi's sarcoma-associated herpesvirus (KSHV) and Epste

184 DSBs) in DNA, although detail concerning how Kaposi's sarcoma-associated herpesvirus (KSHV) modulates

185 Human Kaposi's sarcoma-associated herpesvirus (KSHV) effective

186 n KSHV-infected spindle tumor cells in human Kaposi sarcoma lesions.

187 IL-4 also reactivated human Kaposi's sarcoma-associated herpesvirus from latency in

188 of vGPCR-induced lesions that resemble human Kaposi's sarcoma.

189 Sequence comparisons to human Kaposi's sarcoma-associated herpesvirus (KSHV) miRNAs re

190 ive stages of the KSHV life cycle.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) causes AI

191 ion that is transferable to MHV68.IMPORTANCE Kaposi sarcoma-associated herpesvirus (KSHV) and murine

192 To assess the role of IL-6 in Kaposi sarcoma-associated herpesvirus (KSHV) latency, KS

193 t HIV, together with a transient increase in Kaposi's sarcoma-associated herpesvirus viral load at we

194 n expression was drastically up-regulated in Kaposi sarcoma-like lesions and that loss of IKKepsilon

195 s subfamily of gammaherpesviruses, including Kaposi sarcoma-associated herpesvirus (KSHV) and murine

196 egument proteins of herpesviruses, including Kaposi's sarcoma-associated herpesvirus (KSHV), play key

197 of immunocompromised individuals, including Kaposi's sarcoma (KS).

198 several AIDS-related malignancies, including Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL

199 ked to several human malignancies, including Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL

200 virus (KSHV)-related malignancies, including Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL

201 sal agent of several malignancies, including Kaposi's sarcoma, commonly found in immunocompromised pa

202 n adaptive immunity, many viruses, including Kaposi's sarcoma-associated herpesvirus (KSHV), have evo

203 ted with one of oncogenic viruses infection, Kaposi's sarcoma-associated herpesvirus.

204 Latent Kaposi's sarcoma-associated herpesvirus (KSHV) episomes

205 Latent Kaposi's sarcoma-associated herpesvirus (KSHV) genomes e

206 The maintenance of latent Kaposi's sarcoma-associated herpesvirus (KSHV) genomes i

207 on lymphoma (PEL) cells infected with latent Kaposi's sarcoma-associated herpesvirus (KSHV), the prom

208 Unique to gamma-herpesviruses, like Kaposi's sarcoma-associated herpesvirus and Epstein-Barr

209 a 50 years ago, only one other virus, namely Kaposi's sarcoma-associated herpesvirus/human herpesviru

210 Castleman's disease, as well as its namesake Kaposi's sarcoma.

211 was undertaken to determine whether de novo Kaposi's sarcoma-associated herpesvirus (KSHV) infection

212 Lytic activation of Kaposi's sarcoma-associated herpesvirus (KSHV) from late

213 pesvirus 8 (HHV-8) is the causative agent of Kaposi sarcoma (KS) and multicentric Castleman disease (

214 herpesvirus (KSHV) is the causative agent of Kaposi sarcoma (KS), one of the leading cancers in human

215 herpesvirus (KSHV) is the etiologic agent of Kaposi's sarcoma (KS), a vascular tumor frequently found

216 d herpesvirus (KSHV), the etiologic agent of Kaposi's sarcoma (KS), is present in the predominant tum

217 herpesvirus (KSHV) is the etiologic agent of Kaposi's sarcoma (KS), the most common tumor of AIDS pat

218 herpesvirus (KSHV) is the etiologic agent of Kaposi's sarcoma (KS).

219 erpesvirus 8 (HHV-8), the causative agent of Kaposi's sarcoma and B cell neoplasms in AIDS patients,

220 herpesvirus (KSHV), the etiological agent of Kaposi's sarcoma and primary effusion lymphoma, has deve

221 herpesvirus (KSHV) is the causative agent of Kaposi's sarcoma, and a constitutively active viral G pr

222 d herpesvirus (KSHV), the causative agent of Kaposi's sarcoma, encodes 25 mature viral miRNAs.

223 rs.IMPORTANCE KSHV is the etiologic agent of Kaposi's sarcoma, the most common tumor of AIDS patients

224 d herpesvirus (KSHV), the etiologic agent of Kaposi's sarcoma.

225 The burden of Kaposi sarcoma (KS) in human immunodeficiency virus (HIV

226 Therefore, an understanding of the burden of Kaposi's sarcoma (KS) and non-Hodgkin lymphoma (NHL) rel

227 i sarcoma herpesvirus (KSHV) is the cause of Kaposi sarcoma (KS), primary effusion lymphoma (PEL), an

228 ssociated herpesvirus (KSHV) is the cause of Kaposi's sarcoma (KS), which is the most common AIDS-ass

229 ere, we identify a viral trimeric complex of Kaposi's sarcoma-associated herpesvirus (KSHV) open read

230 ncy is an integral part of the life cycle of Kaposi's sarcoma-associated herpesvirus (KSHV), an etiol

231 rpesvirus 8) is linked to the development of Kaposi's sarcoma (KS), primary effusion lymphoma (PEL),

232 s tightly associated with the development of Kaposi's sarcoma and multicentric Castleman's disease, a

233 Ca-SP also inhibited entry of Kaposi sarcoma-associated herpesvirus/human herpes virus

234 ent SCFAs stimulate lytic gene expression of Kaposi's sarcoma-associated herpesvirus (KSHV) dose depe

235 s etiologically associated with all forms of Kaposi's sarcoma worldwide.

236 n by HIV-1 promotes the aggressive growth of Kaposi's sarcoma-associated herpesvirus (KSHV)-related m

237 Kaposi sarcoma is caused by infection of Kaposi sarcoma-associated herpesvirus (KSHV) and is char

238 latency-associated nuclear antigen (LANA) of Kaposi sarcoma herpesvirus (KSHV) is mainly localized an

239 We report that ORF10 of Kaposi's sarcoma-associated herpesvirus (KSHV), a nuclea

240 encoded by open reading frame 36 (ORF36) of Kaposi's sarcoma-associated herpesvirus (KSHV) enhances

241 for lifelong persistence and pathogenesis of Kaposi's sarcoma-associated herpesvirus (KSHV).

242 High prevalence of Kaposi's sarcoma (KS) is seen in diabetic patients.

243 The K1 gene product of Kaposi's sarcoma-associated herpesvirus (KSHV) is encode

244 al role in the initiation and progression of Kaposi's sarcoma tumors.

245 factor in the development and progression of Kaposi's sarcoma-associated herpesvirus (KSHV)-induced p

246 The K15P membrane protein of Kaposi's sarcoma-associated herpesvirus (KSHV) interacts

247 The ORF45 protein of Kaposi's sarcoma-associated herpesvirus (KSHV) is a gamm

248 lytic phases.IMPORTANCE The K15P protein of Kaposi's sarcoma-associated herpesvirus (KSHV) is though

249 , an immediate-early and tegument protein of Kaposi's sarcoma-associated herpesvirus (KSHV), causes s

250 inity tagged and purified all 89 proteins of Kaposi's sarcoma-associated herpesvirus (KSHV) from huma

251 hundreds of genes during the reactivation of Kaposi's sarcoma-associated herpesvirus (KSHV).

252 Specific regions of Kaposi's sarcoma-associated herpesvirus (KSHV) latent ep

253 r maturation of RRV, the closest relative of Kaposi's sarcoma-associated herpesvirus (KSHV) (a human

254 Latent DNA replication of Kaposi's sarcoma-associated herpesvirus (KSHV) initiates

255 o-electron microscopy (cryo-EM) structure of Kaposi's sarcoma-associated herpesvirus (KSHV) virion, a

256 tients at the Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic infections (GHESKIO)

257 Of interest, treatment of Kaposi's sarcoma (KS) patients with rapamycin provided t

258 iral FLICE-like inhibitor protein (vFLIP) of Kaposi's sarcoma-associated herpesvirus (KSHV), against

259 Effects of Ca-SP on Kaposi sarcoma-associated herpesvirus/human herpes virus

260 Oncogenic Kaposi's sarcoma-associated herpesvirus (KSHV) has laten

261 The human oncogenic Kaposi's sarcoma-associated herpesvirus (KSHV) expresses

262 ng protein (vFLIP), encoded by the oncogenic Kaposi sarcoma-associated herpes virus (KSHV), constitut

263 ce of first posttransplant SCC, melanoma, or Kaposi sarcoma of the skin.

264 tential risk factors for development of oral Kaposi's sarcoma (KS).

265 ose relative of the human oncogenic pathogen Kaposi's sarcoma-associated herpesvirus, ORF52 is a high

266 ed herpesvirus (KSHV)-induced posttransplant Kaposi's sarcoma (KS).

267 sociated substrate) as a platform to promote Kaposi's sarcoma-associated herpesvirus (KSHV) trafficki

268 Purpose Kaposi's sarcoma (KS) is a multicentric tumor caused by

269 SHV) is the cause of aggressive AIDS-related Kaposi's sarcoma (AIDS-KS) characterized by abnormal ang

270 ecimens of 11 HIV-related, 7 non-HIV-related Kaposi sarcoma (KS), and 7 normal skin tissues (NSTs) of

271 nprecedented mechanism of viral replication: Kaposi's sarcoma-associated herpesvirus (KSHV) stably cl

272 at the constitutive AMPK activity restricted Kaposi's sarcoma-associated herpesvirus (KSHV) lytic rep

273 Similarly, Kaposi's sarcoma-associated herpesvirus also did not sti

274 We have previously discovered that Kaposi's sarcoma-associated herpesvirus (KSHV) evades th

275 We report here that Kaposi's sarcoma-associated herpesvirus (KSHV) ORF52, an

276 We recently showed that Kaposi's sarcoma-associated herpesvirus (KSHV, or human

277 The Kaposi's sarcoma-associated herpesvirus (KSHV) LANA prot

278 The Kaposi's sarcoma-associated herpesvirus (KSHV) open read

279 The Kaposi's sarcoma-associated herpesvirus (KSHV) ORF36 pro

280 The Kaposi's sarcoma-associated herpesvirus (KSHV) ORF57 gen

281 , a multifunctional protein expressed by the Kaposi sarcoma-associated herpesvirus (KSHV) in latently

282 e found that most transcripts encoded by the Kaposi's sarcoma-associated herpesvirus (KSHV) genome un

283 ous transcription across the entirety of the Kaposi's sarcoma-associated herpesvirus (KSHV) genome an

284 ncy-associated nuclear antigen (LANA) of the Kaposi's sarcoma-associated herpesvirus (KSHV) performs

285 an effective small-animal model to study the Kaposi's sarcoma-associated herpesvirus (KSHV) infection

286 s, the cofactor activity (CFA), by using the Kaposi's sarcoma-associated herpesvirus RCA homolog Kapo

287 a human gammaherpesvirus casually linked to Kaposi's sarcoma (KS), multicentric Castleman's disease

288 rld primates and are distinct but related to Kaposi's sarcoma-associated herpesvirus (KSHV), the etio

289 ssociated with the endothelial-derived tumor Kaposi sarcoma.

290 esvirus 8, is the etiologic agent underlying Kaposi sarcoma, primary effusion lymphoma, and multicent

291 d levels of viral lytic gene expression when Kaposi's sarcoma-associated herpesvirus (KSHV) infected

292 irus (KSHV) is etiologically associated with Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL

293 irus (KSHV) is etiologically associated with Kaposi's sarcoma (KS), primary effusion lymphoma (PEL),

294 mmaherpesvirus etiologically associated with Kaposi's sarcoma, a vascular tumor of endothelial cells.

295 L) is a lymphogenic disorder associated with Kaposi's sarcoma-associated herpesvirus (KSHV) infection

296 of care for patients with HIV diagnosed with Kaposi's sarcoma (KS), but the current role of systemic

297 ected cells.IMPORTANCE B cells infected with Kaposi's sarcoma-associated herpesvirus (KSHV) harbor mu

298 rophoretic response of B cells infected with Kaposi's sarcoma-associated herpesvirus (KSHV) were inve

299 ual men were over-represented among men with Kaposi's sarcoma (OR, 48.2; 95% CI, 22.0 to 105.6), anal

300 tified epithelium, similar to that seen with Kaposi's-associated herpesvirus.

301 e expression occurs upon superinfection with Kaposi's sarcoma-associated herpesvirus (KSHV), a common